Targeted therapy proves effective against aggressive rare blood cancer
A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Details on the trial, which supported ...
Apr 24, 2019
0
23